In today’s recent session, 1.94 million shares of the AbCellera Biologics Inc (NASDAQ:ABCL) have been traded, and its beta is 0.37. Most recently the company’s share price was $3.13, and it changed around -$0.07 or -2.03% from the last close, which brings the market valuation of the company to $935.75M. ABCL at last check was trading at a discount to its 52-week high of $3.68, offering almost -17.57% off that amount. The share price’s 52-week low was $1.89, which indicates that the recent value has risen by an impressive 39.62% since then.
AbCellera Biologics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.25. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended ABCL as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Instantly ABCL has been showing red trend so far today with a performance of -2.03% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.57 on recent trading dayincreased the stock’s daily price by 12.32%. The company’s shares are currently up 7.00% year-to-date, but still up 24.90% over the last five days. On the other hand, AbCellera Biologics Inc (NASDAQ:ABCL) is 55.20% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $23.5, which translates to bulls needing to increase their stock price by 86.68% from its current value. Analyst projections state that ABCL is forecast to be at a low of $5 and a high of $34.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -107.74%. AbCellera Biologics Inc earnings are expected to increase by -10.77% in 2025, but the outlook is positive 0.83% per year for the next five years.
ABCL Dividends
AbCellera Biologics Inc’s next quarterly earnings report is expected to be released in July.
BAILLIE GIFFORD & CO, with 7.4472% or 21.91 million shares worth $64.86 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
